---
title: "D.A. Davidson Reaffirms Their Buy Rating on Crane Company (CR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294247332.md"
description: "D.A. Davidson analyst Matt Summerville reaffirmed a Buy rating on Crane Company (CR) with a $235 price target. Stifel Nicolaus also maintained a Buy rating, setting a higher target of $242. Both firms express positive outlooks on the stock."
datetime: "2026-07-29T17:35:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294247332.md)
  - [en](https://longbridge.com/en/news/294247332.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294247332.md)
generator: "portal-rs"
---

# D.A. Davidson Reaffirms Their Buy Rating on Crane Company (CR)

In a report released today, Matt Summerville from D.A. Davidson maintained a Buy rating on Crane Company, with a price target of $235.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Summerville is a 5-star analyst with an average return of 14.6% and a 56.38% success rate. Summerville covers the Industrials sector, focusing on stocks such as Columbus Mckinnon, Franklin Electric Co, and Graco.

In a report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $242.00 price target.

### Related Stocks

- [CR.US](https://longbridge.com/en/quote/CR.US.md)
- [CMCO.US](https://longbridge.com/en/quote/CMCO.US.md)
- [FELE.US](https://longbridge.com/en/quote/FELE.US.md)
- [GGG.US](https://longbridge.com/en/quote/GGG.US.md)

## Related News & Research

- [Crane director James L. L. Tullis disposes of 400 shares worth $82,150](https://longbridge.com/en/news/297829295.md)
- [Arrowstreet Capital Limited Partnership Decreases Position in Crane $CR](https://longbridge.com/en/news/295316782.md)
- [Moleculin Biotech highlights interim Phase 3 AML data for annamycin showing 36% CR, 54% CRc in pooled arms](https://longbridge.com/en/news/297668239.md)
- [Hyperscale Data forecasts 2027 revenue of $300 million-$350 million, adjusted EBITDA of $60 million-$80 million](https://longbridge.com/en/news/297894890.md)
- [Balanced Risk-Reward Keeps Asana at Hold Amid AI-Driven Demand but Pricing Transition Headwinds](https://longbridge.com/en/news/297986018.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**